Status:
COMPLETED
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC
Lead Sponsor:
Thoraxklinik-Heidelberg gGmbH
Collaborating Sponsors:
AstraZeneca
Conditions:
EGFR Positive Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases a...
Eligibility Criteria
Inclusion
- histologically confirmed locally advanced (stage III) and not suitable for definitive local treatment, or metastatic (stage IV) NSCLC
- activating EGFR mutation confirmed
- treatment with EGFR TKI
Exclusion
- none
Key Trial Info
Start Date :
April 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04105153
Start Date
April 15 2019
End Date
December 1 2019
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg
Heidelberg, Germany, 69126